In this study, we aimed to explore the expression levels of anti-COPT1 autoantibodies in the plasma of NSCLC patients, and their potential as biomarkers for the clinical diagnosis of NSCLC. This evidence concerns the gene SLC31A1 and non-small cell lung carcinoma.